Literature DB >> 34348706

Role of obesity and hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes.

Lucia La Sala1, Antonio E Pontiroli2.   

Abstract

In a cohort study performed using primary care databases in a General Practitioners Network, Groenewegen et al. report a clear association between diabetes and incidence of the major chronic progressive heart diseases, notably heart failure (Groenewegen et al. in Cardiovasc Diabetol 20:123, 2021). However, no mention is made of body mass index and hypertension in the methods or in the results. Obesity is linked to hypertension and hypertension is a major risk factor for all cardiovascular diseases, and prospective studies have shown that obesity and hypertension contribute significantly to atrial fibrillation in persons with diabetes. The data would be improved by assessing the role of obesity and of hypertension in the incidence of heart diseases in these patients. This would also lead to a better and personalized treatment of patients with diabetes, for instance through weight loss and intensification of treatment of hypertension, to modify the incidence of atrial fibrillation, ischaemic heart disease and heart failure.
© 2021. The Author(s).

Entities:  

Keywords:  Atrial fibrillation; Diabetes mellitus; Heart failure; Hypertension; Ischaemic heart disease; Obesity

Year:  2021        PMID: 34348706      PMCID: PMC8340472          DOI: 10.1186/s12933-021-01331-5

Source DB:  PubMed          Journal:  Cardiovasc Diabetol        ISSN: 1475-2840            Impact factor:   9.951


Sir, In a recent paper Groenewegen et al. report on the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes [1] in the Netherlands. In a longitudinal cohort study performed using primary care databases in a General Practitioners Network, the authors show a clear association between diabetes and incidence of the major chronic progressive heart diseases, notably heart failure, with a more than twice increased risk. However, in this study no mention is made of body mass index in the “Methods” section or in the “Results” section. Even though the primary interest was to describe the incidence of cardiovascular diseases in diabetes in the real world, the data would gain scientific value by dissecting the role of obesity itself in the incidence of cardiovascular diseases, possibly mediated by hypertension. In fact, obesity is associated with hypertension [2], and hypertension is a major risk factor for all cardiovascular diseases, including coronary heart disease, stroke, atrial fibrillation, heart failure, aortic and peripheral arterial disease, and valvular heart disease [3]. In the prospective cross‑sectional observational NOMED‑AF (Non‑ invasive Monitoring for Early Detection of Atrial Fibrillation) study performed in Poland, atrial fibrillation was observed in 25 % persons with diabetes as compared with 17% persons without diabetes [4]; also, persons with diabetes and atrial fibrillation had more frequently hypertension, obesity, and ischemic heart disease than persons without diabetes. There is no doubt that blood glucose levels represent a direct risk factor for cardiovascular diseases, of increasing value from prediabetes to diabetes, to insulin-treated diabetes [5, 6]. However, the cardiovascular risk gradually increases with increases in blood pressure regardless of the presence of and of the degree of glucose abnormality [7]. Finally, one should consider education and healthy habits of persons with diabetes; in Sweden, less educated people had a poor prognosis and a higher prevalence of CVD risk factors (including poor glycemic control, smoking and obesity) than well educated people [8]. Therefore, it seems wise to assume that diabetes is not a lonely actor responsible for atrial fibrillation, ischaemic heart disease and heart failure. The data of Groenewegen et al. [1] would be improved by assessing, likely through multivariable analysis, the role of obesity and of hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in their patients. This would also lead to a better and personalized treatment of patients with diabetes, for instance through weight loss and intensification of treatment of hypertension, to modify the incidence of atrial fibrillation, ischaemic heart disease and heart failure [2].
  8 in total

1.  Associations of Systolic Blood Pressure and Diastolic Blood Pressure With the Incidence of Coronary Artery Disease or Cerebrovascular Disease According to Glucose Status.

Authors:  Mayuko Harada Yamada; Kazuya Fujihara; Satoru Kodama; Takaaki Sato; Taeko Osawa; Yuta Yaguchi; Masahiko Yamamoto; Masaru Kitazawa; Yasuhiro Matsubayashi; Takaho Yamada; Hiroyasu Seida; Wataru Ogawa; Hirohito Sone
Journal:  Diabetes Care       Date:  2021-05-25       Impact factor: 19.112

Review 2.  High Blood Pressure and Cardiovascular Disease.

Authors:  Flávio D Fuchs; Paul K Whelton
Journal:  Hypertension       Date:  2019-12-23       Impact factor: 10.190

3.  Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project.

Authors:  Arjun Sinha; Hongyan Ning; Faraz S Ahmad; Michael P Bancks; Mercedes R Carnethon; Matthew J O'Brien; Norrina B Allen; John T Wilkins; Donald M Lloyd-Jones; Sadiya S Khan
Journal:  Cardiovasc Diabetol       Date:  2021-03-22       Impact factor: 8.949

4.  High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery.

Authors:  Lucia La Sala; Elena Tagliabue; Elaine Vieira; Antonio E Pontiroli; Franco Folli
Journal:  Cardiovasc Diabetol       Date:  2021-06-09       Impact factor: 9.951

5.  Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes.

Authors:  Amy Groenewegen; Victor W Zwartkruis; Betül Cekic; Rudolf A de Boer; Michiel Rienstra; Arno W Hoes; Frans H Rutten; Monika Hollander
Journal:  Cardiovasc Diabetol       Date:  2021-06-16       Impact factor: 9.951

6.  Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study.

Authors:  Jakub Gumprecht; Gregory Y H Lip; Adam Sokal; Beata Średniawa; Katarzyna Mitręga; Jakub Stokwiszewski; Łukasz Wierucki; Aleksandra Rajca; Marcin Rutkowski; Tomasz Zdrojewski; Tomasz Grodzicki; Jarosław Kaźmierczak; Grzegorz Opolski; Zbigniew Kalarus
Journal:  Cardiovasc Diabetol       Date:  2021-06-24       Impact factor: 9.951

7.  Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.

Authors:  Gregory G Schwartz; Stephen J Nicholls; Peter P Toth; Michael Sweeney; Christopher Halliday; Jan O Johansson; Norman C W Wong; Ewelina Kulikowski; Kamyar Kalantar-Zadeh; Henry N Ginsberg; Kausik K Ray
Journal:  Cardiovasc Diabetol       Date:  2021-06-22       Impact factor: 9.951

8.  Mortality rates and cardiovascular disease burden in type 2 diabetes by occupation, results from all Swedish employees in 2002-2015.

Authors:  Sofia Carlsson; Tomas Andersson; Mats Talbäck; Maria Feychting
Journal:  Cardiovasc Diabetol       Date:  2021-06-26       Impact factor: 9.951

  8 in total
  1 in total

Review 1.  The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis.

Authors:  Jiwen Fan; Meng Ren; Binay Kumar Adhikari; Haodong Wang; Yuquan He
Journal:  J Inflamm Res       Date:  2022-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.